Which action most effectively guides dosing decisions for elderly patients starting a new medication?

• A. Renal and hepatic function tests
• B. Electrolyte panel alone
• C. Pulmonary function tests
• D. Hearing screening only

Answer: (A)

Dosing decisions for older adults hinge on how well the drug is cleared from the body. Age-related declines in kidney and liver function often change how quickly a medication is eliminated or metabolized, increasing the risk of drug accumulation and toxicity if standard doses are used. Therefore, renal and hepatic function tests provide the most direct information to tailor the starting dose and subsequent adjustments. Renal function measurements (like creatinine clearance or estimated GFR) tell you how efficiently the kidneys will excrete the drug, so you can reduce the dose or extend dosing intervals if clearance is reduced. Hepatic function tests (ALT, AST, alkaline phosphatase, bilirubin, and related markers) indicate the liver’s ability to metabolize many drugs, guiding adjustments for drugs that rely on hepatic metabolism or have high protein binding.

In contrast, an electrolyte panel shows electrolyte status relevant to certain drugs but doesn’t reveal overall drug clearance or metabolism. Pulmonary function tests are mainly useful for drugs affecting the respiratory system or for patients with respiratory disease, not for general dosing of most systemic medications. Hearing screening has no direct relevance to pharmacokinetics or dosing decisions.